Back to Registry

Body Protection Compound-157

Also known as: BPC-157, Pentadecapeptide

Research Only

Molecular Formula

C62 H98 N16 O22

Molecular Weight

1,419.556 Da

Half-Life

< 30 minutes (plasma, mammalian models)

Sequence

GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)

Clinical Applications & Evidence

Mechanism of Action

BPC-157 operates via multiple interconnected molecular cascades. It primarily uncouples Caveolin-1 from endothelial nitric oxide synthase (eNOS), thereby rapidly increasing localized nitric oxide production to regulate vascular tone and repair. Concurrently, it activates the VEGFR2 receptor and subsequent Akt-eNOS and ERK1/2 pathways, leading to the nuclear transcription of growth factors (such as Egr-1, c-Fos, and c-Jun) that govern cellular proliferation, fibroblast migration, and organized angiogenesis. Neurologically, it acts as a neuromodulator, protecting dopaminergic and serotonergic neurons from toxin-induced depletion and receptor blockade.

Investigated Uses

  • Tendon and ligament repair
  • Gut healing and inflammatory bowel conditions
  • Muscle injury recovery
  • Neuroprotection
  • Wound healing acceleration
Early Clinical / Animal Models

Regulatory & Safety Status

FDA Status

Research Only

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

Nausea (rare)Dizziness (rare)Injection site irritation

Contraindications

  • Pregnancy and breastfeeding
  • Active cancer (theoretical angiogenesis concern)

Drug Interactions

  • May interact with blood pressure medications
  • Theoretical interaction with anticoagulants

Citations & Clinical Trials

PubMed Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract MDPI Pharmaceuticals BPC 157 Characteristics — Structural Analysis, Targeted Receptors/Molecular Pathways PubMed Central Molecular Pathways of BPC-157 in Musculoskeletal Healing